The spectrum of giant cells in tumours of the salivary glands: an analysis of 11 cases.
In view of the different terminology for salivary gland tumours with giant cells, eleven cases were analysed by histopathology and immunocytochemistry. Four cases (three pleomorphic adenomas, one carcinosarcoma in a pleomorphic adenoma) were classified as having a foreign-body giant cell reaction, and five cases (two mucoepidermoid carcinomas, one acinic cell carcinoma, two carcinomas in pleomorphic adenomas) as having a sarcomatoid osteoclast-like giant cell reaction. In two further cases a giant cell tumour and a giant cell granuloma were associated with carcinomas in pleomorphic adenomas. All giant cells showed characteristic expression of CD68 as a typical marker for histiocytes and macrophages with their origin in mononuclear haematopoetic stem cells. There was no evidence for an epithelial origin of the giant cells because all those examined had a negative reaction to cytokeratin. Foreign-body cells were characterized by cytoplasmic vacuoles and irregularly dispersed nuclei. They showed a focally circumscribed reaction mostly outside the connective tissue pseudocapsule of the tumours. The sarcomatoid osteoclast-like giant cell reactions in carcinomas were distinctly intermingled with the carcinomatous patterns. In contrast, the associated osteoclast-like giant cell tumour was distinctly separate from the salivary gland tumour tissue and was composed of numerous larger osteoclast-like giant cells with a greater number of nuclei (more than 20); these giant cells were uniformly distributed throughout the tumour tissue. The giant cell granuloma was also separate from the carcinoma and was composed of nests of smaller, more irregularly distributed giant cells.
Donath
K
K
Department of Oral Pathology, University of Hamburg, Germany.
Seifert
G
G
Röser
K
K
D008949:Adenoma, Pleomorphic / Q000473:pathology; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D002277:Carcinoma / Q000473:pathology; D018267:Carcinoma, Acinar Cell / Q000473:pathology; D018277:Carcinoma, Mucoepidermoid / Q000473:pathology; D002296:Carcinosarcoma / Q000473:pathology; D019070:Cell Lineage; D002467:Cell Nucleus / Q000648:ultrastructure; D003238:Connective Tissue / Q000473:pathology; D004847:Epithelial Cells / Q000473:pathology; D005549:Foreign-Body Reaction / Q000473:pathology; D005870:Giant Cell Tumors / Q000473:pathology; D015726:Giant Cells / Q000145:classification / Q000473:pathology*; D015743:Giant Cells, Foreign-Body / Q000473:pathology; D006101:Granuloma, Giant Cell / Q000473:pathology; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006644:Histiocytes / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008264:Macrophages / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000473:pathology; D010010:Osteoclasts / Q000473:pathology; D012468:Salivary Gland Neoplasms / Q000473:pathology*; D012509:Sarcoma / Q000473:pathology; D014617:Vacuoles / Q000648:ultrastructure; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; D007633:Keratins; C067980:CD68 antigen, human; D000097382:CD68 Molecule